Mineralys Therapeutics, Inc. MLYS R&D credit carryforward
R&D credit carryforward at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.
The official record: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s r&d credit carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s r&d credit carryforward?
- Mineralys Therapeutics, Inc. (MLYS) reported r&d credit carryforward of $21.17M in Q4 2025.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s r&d credit carryforward?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s r&d credit carryforward has grown at a 149.9% compound annual growth rate (CAGR), from $1.36M to $21.17M.
- What does r&d credit carryforward mean?
- This represents the accumulated value of research and development tax credits that a company has earned but has not yet utilized to offset its tax liabilities. These carryforwards provide a potential future tax shield, which can improve cash flow once the company achieves profitability. For clinical-stage biopharmaceutical firms, this asset reflects the historical investment in innovation and the potential for future tax efficiency.